We are pleased to welcome Dr Rick Hibbert as NecstGen’s new Chief Executive Officer, effective 1 October 2025.

Rick is an experienced leader in the biopharmaceutical industry, with a strong background in innovation, development, and manufacturing. He joins NecstGen from Genmab, an international biotechnology company focused on developing therapeutic antibodies to treat cancer, where he served as Vice President and Head of CMC Science and Technologies.
Rick received his PhD at the University of Oxford in 2005 and obtained his MBA in 2013.

At NecstGen, Rick will lead our mission to empower the next generation of Cell and Gene Therapy innovators, accelerating the path from research to patients worldwide. As a development and manufacturing centre, NecstGen supports both academic and industrial partners in advancing pioneering therapies. We are proud to collaborate with leading researchers on innovative projects like Gene Therapy to treat Duchenne’s Muscular Dystrophy and new stem cell treatments for diabetes. Rick’s leadership will be key in driving these initiatives forward.

We extend our sincere thanks to Chief Operating Officer Arjen Schippers and Chief Financial Officer Jan Rydlo for their leadership during this transition period.